Ligand Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Ligand Pharmaceuticals using advanced sorting and filters.
Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-27 | $1.27 | $1.19 | 6.72 % |
Q3 | 2024-11-07 | $1.84 | $1.35 | 36.3 % |
Q2 | 2024-08-06 | $1.40 | $0.98 | 42.9 % |
Q1 | 2024-05-07 | $3.84 | $0.78 | 392.3 % |
Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Q4 | 2025-02-27 | $42.81M | $39.03M | 9.69 % |
Q3 | 2024-11-07 | $51.81M | $40.65M | 27.5 % |
Q2 | 2024-08-06 | $41.53M | $31.90M | 30.2 % |
Q1 | 2024-05-07 | $30.98M | $27.92M | 10.9 % |
Ligand Pharmaceuticals (LGND) is scheduled to report earnings on May 6, 2025. The last reported earnings were for reported on February 27, 2025 for Q4.
The Actual EPS was $1.27, which beat the estimate of $1.19.
The Actual Revenue was $42.8M, which beat the estimate of $39M.
Browse earnings estimates, EPS, and revenue on all stocks.